Medtech firm Mainstay gathers €25m war chest to chase FDA
The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its back pain treatment next year
Medical device maker Mainstay has raised almost €17 million in cash from investors as it attempts to secure approval for its chronic back pain treatment.
The cash call is double the figure it had set itself earlier this year as it begins a push for US drug regulators to sign off on its treatment next year. The fundraising will also allow it to draw down a further €3 million loan.
The money is being provided...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month, €19.99 Monthly thereafter
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
Tom Maguire: Tax changes we make now could help business for years
The way we did business a few months ago may never return – so the opportunity is to make changes that will both aid recovery and set us up well for our new futures
The Daily Briefing
What’s coming up today and what you might have missed
The Daily Briefing
What’s coming up today and what you might have missed.
